Valuation: Apellis Pharmaceuticals, Inc.

Market Cap 5.25B 4.55B 4.27B 3.89B 7.32B 501B 7.44B 50.26B 19.62B 251B 19.72B 19.29B 837B P/E 2027 *
342x
P/E 2028 * 38.3x
Enterprise Value 5.25B 4.55B 4.27B 3.89B 7.32B 501B 7.44B 50.26B 19.62B 251B 19.72B 19.29B 837B EV / Sales 2027 *
5.06x
EV / Sales 2028 * 4.35x
Free-Float
88.57%
Yield 2027 *
-
Yield 2028 * -

Last Transcript: Apellis Pharmaceuticals, Inc.

1 day-0.07%
6 months+89.08%
Current year+63.34%
Current year 16.83
Extreme 16.83
41.14
1 year 16.83
Extreme 16.83
41.14
3 years 16.1
Extreme 16.1
73.8
5 years 16.1
Extreme 16.1
94.75
10 years 11.45
Extreme 11.45
94.75
Manager TitleAgeSince
Chief Operating Officer 56 2009-09-24
Director of Finance/CFO 55 2017-09-30
Chief Tech/Sci/R&D Officer - 2025-08-24
Date Insider Type Main position Quantity % Market Cap.
5/14/26 Tender

Founder

-1,991,703 1.5581%
2/27/26 Free

Director

38,447 0.0304%
2/11/26 Sell

Executive/Senior Manager

368 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
-0.07%-.--%+54.36%+26.67% 5.25B
+1.00%+4.39%+43.53%-0.12% 80.48B
+0.97%+3.30%-2.19%+26.99% 51.06B
-1.05%-2.82%+11.58%+163.94% 48.19B
-0.74%+3.26%-49.46%-48.10% 46.5B
+0.85%+2.12%+55.82%-23.03% 31.12B
-0.03%+18.18%+136.71%-37.28% 25.41B
-0.21%+1.81%+40.38%+82.80% 24.43B
-1.42%-1.11%-2.29%+189.51% 21.11B
-1.38%-2.34%+62.72%+106.63% 16.28B
Average -0.15%+3.33%+35.12%+48.80% 34.98B
Weighted average by Cap. +0.07%+3.18%+26.03%+37.93%

Financials

2027 *2028 *
Net sales 1.04B 900M 843M 769M 1.45B 99.06B 1.47B 9.93B 3.88B 49.59B 3.9B 3.81B 165B 1.21B 1.05B 982M 896M 1.69B 115B 1.71B 11.57B 4.52B 57.75B 4.54B 4.44B 193B
Net income -34.31M -29.74M -27.88M -25.42M -47.83M -3.27B -48.6M -328M -128M -1.64B -129M -126M -5.47B 90.71M 78.63M 73.71M 67.21M 126M 8.66B 128M 868M 339M 4.33B 341M 333M 14.46B
Net Debt - -
Logo Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom.
Employees
736
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. APLS Stock